Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome – insight from transcriptosome and experimental studies-Reference-Cited by-同舟云学术

Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome – insight from transcriptosome and experimental studies

Published:2016-03-21 Issue:5 Volume:15 Page:647-657
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Michel Martin C.¹^ORCID,Gravas Stavros²

Affiliation:

1. Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany

2. Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

Publisher

Informa Healthcare

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/14740338.2016.1160055

Reference79 articles.

1. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society

2. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study

3. Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?

4. Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach

5. Overactive Bladder Drugs and Constipation: A Meta-Analysis of Randomized, Placebo-Controlled Trials

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the Safety and Effectiveness of α-Blockers Versus Mirabegron for Medical Expulsive Therapy in Ureteral Calculi: A Systematic Review and Meta-Analysis;2024-02-12

2. Inside the Biology of the β3-Adrenoceptor;Biomolecules;2024-01-29

3. Efficacy of mirabegron for ureteral stones: a systematic review with meta-analysis of randomized controlled trials;Frontiers in Pharmacology;2023-12-20

4. Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia;Expert Opinion on Drug Safety;2023-12-02

5. Evaluation of the efficacy and safety of either or both mirabegron and silodosin, as a medical expulsive therapy for distal ureteric stones;International Urology and Nephrology;2023-12-02